DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Synthetic Conjugated Estrogens (Synthetic Conjugated Estrogens) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Cenestin therapy is indicated for the:

  1. Treatment of moderate-to-severe vasomotor symptoms associated with the menopause.
    • 0.45 mg Cenestin
    • 0.625 mg Cenestin
    • 0.9 mg Cenestin
    • 1.25 mg Cenestin
  2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
    • 0.3 mg Cenestin

DOSAGE AND ADMINISTRATION

When estrogen is prescribed for a postmenopausal woman with a uterus, progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary (see BOX WARNINGS and WARNINGS). For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

  1. For treatment of moderate to severe vasomotor symptoms associated with the menopause.
    • Cenestin 0.45 mg
    • Cenestin 0.625 mg
    • Cenestin 0.9 mg
    • Cenestin 1.25 mg
      Patients should be started at Cenestin 0.45 mg daily. Subsequent dosage adjustment may be made based upon the individual patient response.This dose should be periodically reassessed by the healthcare provider. The lowest effective dose of Cenestin for the treatment of moderate to severe vasomotor symptoms has not been determined.
  2. For treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
    • Cenestin 0.3 mg daily

HOW SUPPLIED

Cenestin (synthetic conjugated estrogens, A) Tablets are available as:

0.3 mg:         Round, green, film-coated, and are debossed with letters, dp, and number, 41.

                    Available in bottles of:

                    30                                        NDC 51285-441-30

                    100                                      NDC 51285-441-02

                    1000                                    NDC 51285-441-05

0.45 mg:       Round, orange, film-coated, and are debossed with letters, dp, and number, 46.

                    Available in bottles of:

                    30                                        NDC 51285-446-30

                    100                                      NDC 51285-446-02

                    1000                                    NDC 51285-446-05

0.625 mg:     Round, red, film-coated, and are debossed with letters, dp, and number, 42.

                    Available in bottles of:

                    30                                        NDC 51285-442-30

                    100                                      NDC 51285-442-02

                    1000                                    NDC 51285-442-05

0.9 mg:         Round, white, film-coated, and are debossed with letters, dp, and number, 43.

                    Available in bottles of:

                    30                                        NDC 51285-443-30

                    100                                      NDC 51285-443-02

                    1000                                    NDC 51285-443-05

1.25 mg:       Round, blue, film-coated, and are debossed with letters, dp, and number, 44.

                    Available in bottles of:

                    30                                        NDC 51285-444-30

                    100                                      NDC 51285-444-02

                    1000                                    NDC 51285-444-05

Store at 20-25°C (68-77°F); excursions are permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature].

Dispense in tight container.

Dispense in child-resistant packaging.

Pharmacist: Include one "Information for the patient" leaflet with each package dispensed.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017